Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
N. Kanellakis (Oxford, United Kingdom), R. Asciak (Oxford, United Kingdom), X. Yao (Oxford, United Kingdom), Y. Peng (Oxford, United Kingdom), M. Mccole (Oxford, United Kingdom), S. Mcgowan (Oxford, United Kingdom), R. Mercer (Oxford, United Kingdom), R. Hallifax (Oxford, United Kingdom), T. Sherrill (Nashville, United States of America), F. Maldonado (Nashville, United States of America), D. Ebner (Oxford, United Kingdom), T. Blackwell (Nashville, United States of America), G. Stathopoulos (Patras, Greece), T. Dong (Oxford, United Kingdom), N. Rahman (Oxford, United Kingdom), I. Psallidas (Oxford, United Kingdom). Patient derived pleural mesothelioma cell lines, can be used as tools, to guide patient stratification. 3798

Member's Comments

No comment yet.

Related content which might interest you: Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Breath analysis allows to predict treatment response in malignant pleural mesothelioma patients. Source: Virtual Congress 2021 – Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease Year: 2021 Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer Source: Annual Congress 2005 - What's new in the pleura Year: 2005 Is pleural VEGF a useful parameter? Source: Annual Congress 2007 - Pleural malignancy Year: 2007 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 A comparative study of conventional cytology and cell block method in the diagnosis of malignant pleural effusion. Source: International Congress 2018 – Lung cancer: new tools for diagnosis and patient assessment Year: 2018 Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Proliferation controlling intercellular signalling pathways in human pleural malignant mesothelioma Source: Annual Congress 2007 - Pleural malignancy Year: 2007 Clinical and morphological prognostic factors in patients with malignant pleura mesothelioma (MPM) Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 The smellprint of mesothelioma cells: intrinsic biomarkers for diagnosis and subtyping Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Biological characteristics of dendritic cells from malignant pleural effusions in patients with lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Late-breaking abstract: Tumor marker pattern in benign pleural effusion investigation. A case report of increased pleural CA 125 Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 A novel proteomic technique to identify new diagnostic biomarkers for malignant pleural mesothelioma: a feasibility study. Source: Virtual Congress 2021 – Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease Year: 2021 Population-based survival for malignant mesothelioma after introduction of novel chemotherapy Source: Eur Respir J 2012; 40: 185-189 Year: 2012 Heterogeneous delivery of definitive interventions in malignant pleural effusions – results from a Danish survey. Source: International Congress 2019 – Pleural disease: applying the evidence Year: 2019 Tumor-derived tumor necrosis factor-α promotes Lewis lung cancer-induced malignant pleural effusions in mice Source: Annual Congress 2006 - Molecular pathology and genetics of lung cancer Year: 2006 Time to diagnosis and time to therapy in patients with malignant pleural mesothelioma (MPM) compared to patients with lung cancer in Denmark 2007 to 2011. A quality assurance analysis Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012 Analysis of T-cell subsets in patients with tuberculous pleural effusions Source: Annual Congress 2005 - Genetics and immunobiology of tuberculosis Year: 2005 Validation and comparison of several published prognostic systems for patients with small cell lung cancer Source: Eur Respir J 2011; 38: 657-663 Year: 2011